TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03777982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Apalutamide also prevents the androgens from working within the prostate cancer cells, and can ultimately lead to cancer cell death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Abiraterone acetate interferes with an enzyme that is expressed in testicular, adrenal, and prostatic tumor tissues and is required as part of the body's androgen producing process. Because of this interference the amount of androgens produced are decreased. Abiraterone acetate, blocks androgen production at three sources; the testes, the adrenal glands, as well as from the tumor itself

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH Agonist or Antagonist
Description: Luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or GnRH agonists) are drugs that lower the amount of testosterone made by the testicles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH Agonist or Antagonist
Description: Luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or GnRH agonists) are drugs that lower the amount of testosterone made by the testicles
Study: NCT03737929

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid ablation
Description: In the hybrid ablation arm, the epicardial surgical ablation procedure will be combined with percutaneous endocardial catheter ablation procedure in a single step procedure (same operative time). During the endocardial approach, the isolation of the pulmonary veins and the posterior box will be checked and completed if necessary. Then additional ablation will be performed for atrial tachycardia or ongoing persisting atrial fibrillation (AF) according the same lesions setup or stepwise protocol than the conventional arm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous catheter ablation
Description: In the percutaneous catheter ablation arm, the procedure will be performed according to the current guidelines (pulmonary vein isolation, linear ablation and fragmented potentials ablation if needed, with the achievement of sinus rhythm during the procedure being the optimal endpoint. Any atrial tachycardia will be mapped and ablated as well (DC shock performed otherwise).
Study: NCT06054490

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-management
Description: It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses self-management techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state. In addition, relaxation techniques, sleep hygiene, diet modification, thermotherapy, encouragement to practice social and aerobic activities, and how to prevent risk factors and bad habits.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercises
Description: It is based on home self-exercise routine. Basic exercise therapy includes mobilization, stretching, and muscle strengthening exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercises
Description: It is based on home self-exercise routine. Basic exercise therapy includes mobilization, stretching, and muscle strengthening exercises
Study: NCT02011906

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega 3

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega 3

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin E

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo of omega 3

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: placebo of vitamin E

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo of vitamin E
Study: NCT03841396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride
Description: All participants received a single dose of sodium chloride as placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride
Description: All participants received a single dose of sodium chloride as placebo
Study: NCT01498068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Telaprevir Type = exact number, unit = mg, number = 750, form = tablet, route = oral. Telaprevir 750 mg (2 oral tablets) is taken every 8 hours for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Telaprevir Type = exact number, unit = mg, number = 750, form = tablet, route = oral. Telaprevir 750 mg (2 oral tablets) is taken every 8 hours for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon-alfa-2a
Description: Pegylated-interferon-alfa-2a type = exact number, unit = microgram, number = 180, form = injection, route = subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon-alfa-2a
Description: Pegylated-interferon-alfa-2a type = exact number, unit = microgram, number = 180, form = injection, route = subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin Type = exact, number = 1000 or 1200, unit = mg, form = tablet, route = oral. 1000mg (if participant's weight is \< 75kg) or 1200mg (if participant's weight is \>= 75kg) per day for 24 or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin Type = exact, number = 1000 or 1200, unit = mg, form = tablet, route = oral. 1000mg (if participant's weight is \< 75kg) or 1200mg (if participant's weight is \>= 75kg) per day for 24 or 48 weeks.
Study: NCT03431259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Gateway
Description: Patients will be enrolled in the Patient Gateway app.
Study: NCT01463501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy
Description: Paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f) followed by surgery, consolidate paclitaxel/carboplatin 2 cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy
Description: Surgery followed by paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f), consolidate paclitaxel/carboplatin 2 cycles.
Study: NCT04125927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptamine
Description: Patients will be treated with 1 drop in each eye 4 times a day, at the same dose and regimen than the one indicated in adults and children from 2 years of age.
Study: NCT00940771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boosted Atazanavir
Description: Boosted Atazanavir, once a day dose adjusted for child's weight for 6 months.
Study: NCT04965701

Intervention type: DRUG
Intervention: Osimertinib 80 MG
Description: Osimertinib is administered according to clinical practice at the recommended dose of 80 mg, orally, once a day.
Study: NCT00802308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulphate
Description: Extended release tablet combined with alcohol or water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulphate
Description: Extended release tablet combined with alcohol or water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulphate
Description: Extended release tablet combined with alcohol or water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine sulphate
Description: Extended release tablet combined with alcohol or water
Study: NCT03011099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic exoskeleton training
Description: During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit. Each training session will last up to 90 minutes (60 minutes of training with 30 minutes for setup, don/doff of device) and training will be held 5 days per week for 3 weeks with a total of 15 sessions. During the training period, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: During the training, subjects will receive conventional physical therapy that is designed to facilitate/promote gait. This will include individualized treatment sessions for each subject and may involve stretching, strengthening, balance training, standing, and gait training. Subjects will not be able to participate in any form of robotic assisted or body weight supported treadmill training. Each training session will last up to 60 minutes and training will be held 5 days per week for 3 weeks with a total of 15 sessions. Consistent with the RET group, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise during study period.
Study: NCT04004234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manganese Chloride
Description: Administered by inhalation at 0.2 or 0.4mg/kg/d once daily in a 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Administered intravenously, 125mg/m2/d on day1 and day8 in a 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody
Description: Administered intravenously, 2-4mg/kg on day 3 in a 3-week cycle
Study: NCT00125255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)
Description: S-Caine Peel comprising of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. The study drug was applied at approximately 1 mm in thickness and remained on the treatment area for 30 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Peel
Description: Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
Study: NCT00129246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Participants received naltrexone hydrochloride on the sixth day of bupropion treatment, and the initial dose was 12.5 mg, followed by 25 mg daily for the duration of the 7-week treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period.
Study: NCT00568022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Ixabepilone: Intravenous (IV) Solution, IV, 32(40)mg/m\^2, once every 3 weeks, up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: Tablets, Oral, 1650(2000)mg/m\^2, twice daily for 2 weeks, one week off, up to 6 cycles
Study: NCT04692259

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Liver MRI before liver resection
Study: NCT02246790

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biatrial radiofrequency ablation and CABG
Description: Coronary artery bypass (CABG) using cardio-pulmonary bypass (CPB) and occlusion. Concomitant biatrial RFA during CPB.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial radiofrequency ablation and CABG
Description: Coronary artery bypass (CABG) using cardio-pulmonary bypass (CPB) and occlusion. Concomitant left atrial RFA during CPB.
Study: NCT04409925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhDNase I
Description: Inhaled nebulisations
Study: NCT01670344

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Treatment with investigational method (virtual implant positioning system)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Treatment with surgical standard of care
Study: NCT04084236

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electrical stimulation
Description: electrical stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: no stimulation
Study: NCT03942796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lyrica, vronogabic (pregabalin)
Description: Patients would receive oral pregabalin is initiated at a dose of 75 mg twice daily and titrated up to 600 mg as tolerated by the patient at 1,2,3 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed radiofrequency ablation of the dorsal root ganglion under fluroscopic guidance/ radiofrequency neurolysis/ radiofrequency denervation device name: Neuro Therm TM 1100
Description: Patients would receive pulsed radiofrequency ablation of dorsal root ganglion using the following settings: 2-Hz frequency, 20-ms pulses in a 1 second cycle, 120 second duration and 42°C temperature. Impedance ranges between 150 and 400 Ohms at all levels under fluroscopic guidance. For each pulsed RF application, the procedure will be repeated 4 times, for a total duration of 8 minutes
Study: NCT05153616

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: Full night attended polysomnography to diagnose periodic limb movements
Study: NCT04906564

Intervention type: OTHER
Intervention: Identification of genetic variants
Description: Identification of genetic variants
Study: NCT02786017

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Conventional therapy
Description: Patients will receive the conventional therapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injectable Collagen Scaffold + HUC-MSCs
Description: Injectable collagen scaffold combined with HUC-MSCs was injected into left lateral segment, left medial segment, right anterior segment, right posterior segment and caudate lobe under B-mode ultrasound supervision, respectively. The total amount of HUC-MSCs was 5\*10\^8.
Study: NCT02589938

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Oral Hygiene
Description: Oral hygiene care provided per individual institutions standard of care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Oral Hygiene + True Acupuncture
Description: Oral hygiene care provided per individual institutions standard of care. 14 true acupoint sites will be selected and applied to each participant for 20 minutes at each session. There will be 2 sessions a week for 8 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Oral Hygiene + Sham Acupuncture
Description: Oral hygiene care provided per individual institutions standard of care. 14 sham acupoint sites will be selected and applied to each participant for 20 minutes at each session. There will be 2 sessions a week for 8 weeks.
Study: NCT02680249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-656
Study: NCT02158442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Isolated Limb Perfusion (PILP) delivery
Description: The Percutaneous Isolated Limb Perfusion (PILP) delivery intervention procedure enables the use of existing antibiotic therapies in a more targeted and aggressive fashion; it addresses limitations associated with the use of conventional antibiotic drug delivery. As part of the procedure, the circulation of the limb is isolated separately from the general circulatory system enabling the delivery of antibiotic at high therapeutic doses that are not achievable when standard doses are administered intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timentin
Description: The Control Group will receive standard dosings of intravenous Timentin plus other standard care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timentin
Description: The Control Group will receive standard dosings of intravenous Timentin plus other standard care.
Study: NCT04488614

Intervention type: PROCEDURE
Intervention: Breast Concervative or Meastectomy
Description: National treatment guidelines in Norway
Study: NCT03129568

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDC infusion
Description: Injection of CDCs (0.3 million per kg of body weight).
Study: NCT00613873

Intervention type: PROCEDURE
Intervention: Colonoscopy and Questionnaire
Description: Pt is asked to complete attitude and belief questionnaire then have a Colonoscopy. Then within 6 weeks post colonoscopy a final telephone interview.
Study: NCT01457703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Description: Abolishes pituitary sensitivity to GnRH.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix
Description: Abolishes pituitary sensitivity to GnRH.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadorelin-GnRH
Description: GnRH is used to stimulate the pituitary gland to produce LH and FSH.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadorelin-GnRH
Description: GnRH is used to stimulate the pituitary gland to produce LH and FSH.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant LH
Description: Used to stimulate ovarian function in women.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant LH
Description: Used to stimulate ovarian function in women.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: An aromatase inhibitor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: An aromatase inhibitor.
Study: NCT00622050

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No TV viewing reduction
Description: In the control group, no intervention will be acted upon. This group will receive the exact same protocol as the intervention group, but with observation only.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV viewing reduction
Description: In the experimental arm, TV viewing time will be reduced for half of the study protocol time (3-4 weeks of a 6-8 week protocol).
Study: NCT00828594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001, sorafenib
Study: NCT05716802

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dance/movement therapy
Description: dance/movement therapy plus treat as usual

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: treatment as usual
Description: The patients received regular daily antipsychotic medication and supportive psychotherapy once a week. They also participated in daily activities from Monday to Friday for at least two hours each day, including indoor activities (watching TV, playing games, playing poker) and outside activities (walking and doing radio gymnastics).
Study: NCT00859196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpanthenol (BAY81-2996)
Description: Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
Study: NCT00632229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Paliperidone medication taken daily ranging from 3-9mg/day depending on tolerability and efficacy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill placebo taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
Study: NCT00464633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: 1st dose: 30 mg/m2 as a 30-minute intravenous (IV) infusion followed by 30 mg/m2 as a 4-hour continuous infusion~Then, every treatment week, depending upon the patient's objective response to initial therapy:~* 30 mg/m2 over 30 minutes followed by 50 mg/m2 over 4 hours or~* 30 mg/m2 over 30 minutes followed by 30 mg/m2 over 4 hours.
Study: NCT00306501

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Swallowing Training
Description: Swallowing Training with press of button

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Swallowing Training
Description: Swallowing Training with press of button

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Swallowing Training
Description: Swallowing Training with press of button

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Swallowing Training
Description: Swallowing Training with press of button
Study: NCT00746382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast cream
Description: Roflumilast cream 0.5% versus Placebo cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Placebo cream
Study: NCT02871986

Intervention type: DRUG
Intervention: Routine transdermal oestrogen patch
Description: Transdermal oestrogen patch will be used with an incremental dose increase at 4 months
Study: NCT04794777

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Individualised therapy
Description: Group I - No uptake: treated with conventional SRT against the prostate bed. Group II -Uptake only in the prostate bed: will receive intensity modulated RT (IMRT) including Volumetric Modulated Arc Therapy (VMAT) for prostate bed with simultaneous-integrated boost (SIB) to the PET positive uptake in the prostate bed.~Group III - Uptake in the prostate bed and involvement of regional lymph nodes in the pelvis: will be treated as Group II plus VMAT for the pelvic lymph nodes with SIB to the PET positive lymph nodes or pelvic lymph nodes salvage lymph node dissection (SLND).~Group IV - Uptake in regional lymph nodes only: will be treated with VMAT for the pelvic lymph nodes with SIB to the PET positive lymph nodes or pelvic lymph nodes SLND.~Group V - Uptake in extra-pelvic lymph nodes or bone metastasis: systemic treatment instead of surgery or radiation. Local treatment with surgery or radiation is acceptable if curative intention.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard salvage therapy
Description: Standard salvage radiotherapy